These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31522575)

  • 1. Reasons for not participating in scleroderma patient support groups: a comparison of results from the North American and European scleroderma support group surveys.
    Kwakkenbos L; Carboni-Jiménez A; Carrier ME; Pépin M; Peláez S; Malcarne VL; El-Baalbaki G; Thombs BD;
    Disabil Rehabil; 2021 May; 43(9):1279-1286. PubMed ID: 31522575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reasons for Not Participating in Scleroderma Patient Support Groups: A Cross-Sectional Study.
    Gumuchian ST; Delisle VC; Peláez S; Malcarne VL; El-Baalbaki G; Kwakkenbos L; Jewett LR; Carrier ME; Pépin M; Thombs BD;
    Arthritis Care Res (Hoboken); 2018 Feb; 70(2):275-283. PubMed ID: 28217869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons for attending support groups and organizational preferences: the European scleroderma support group members survey.
    Gumuchian ST; Delisle VC; Kwakkenbos L; Pépin M; Carrier ME; Malcarne VL; Peláez S; El-Baalbaki G; Thombs BD;
    Disabil Rehabil; 2019 Apr; 41(8):974-982. PubMed ID: 29254393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Training and support needs of scleroderma support group facilitators: the North American Scleroderma Support Group Facilitators Survey.
    Delisle VC; Gumuchian ST; El-Baalbaki G; Körner A; Malcarne VL; Peláez S; Carrier ME; Pépin M; Thombs BD;
    Disabil Rehabil; 2019 Oct; 41(20):2477-2482. PubMed ID: 29696997
    [No Abstract]   [Full Text] [Related]  

  • 5. Reasons for non-participation in scleroderma support groups.
    Delisle VC; Gumuchian ST; Pelaez S; Malcarne VL; El-Baalbaki G; Körner A; Hudson M; Baron M; Thombs BD;
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):56-62. PubMed ID: 26950221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reasons for attending support groups and organizational preferences: A replication study using the North American Scleroderma Support Group Survey.
    Pépin M; Kwakkenbos L; Carrier ME; Peláez S; El-Baalbaki G; Malcarne VL; Thombs BD;
    J Scleroderma Relat Disord; 2019 Oct; 4(3):173-186. PubMed ID: 35382506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scleroderma Patient-centered Intervention Network-Scleroderma Support group Leader EDucation (SPIN-SSLED) program: non-randomised feasibility trial.
    Thombs BD; Dyas L; Pépin M; Aguila K; Carrier ME; Tao L; Harb S; Malcarne VL; El-Baalbaki G; Peláez S; Sauve M; Hudson M; Platt RW;
    BMJ Open; 2019 Nov; 9(11):e029935. PubMed ID: 31719073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader EDucation (SPIN-SSLED) Program.
    Thombs BD; Aguila K; Dyas L; Carrier ME; Fedoruk C; Horwood L; Cañedo-Ayala M; Sauvé M; Kwakkenbos L; Malcarne VL; El-Baalbaki G; Peláez S; Connolly K; Hudson M; Platt RW;
    Trials; 2019 Dec; 20(1):717. PubMed ID: 31831073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of training and support programs for leaders of illness-based support groups: commentary and updated evidence.
    Turner KA; Rice DB; Carboni-Jiménez A; Boruff J; Thombs BD
    Syst Rev; 2019 Mar; 8(1):67. PubMed ID: 30836989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Support Groups in Scleroderma.
    Rice DB; Thombs BD
    Curr Rheumatol Rep; 2019 Feb; 21(4):9. PubMed ID: 30790067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and strategies for coping with scleroderma: implications for a scleroderma-specific self-management program.
    Milette K; Thombs BD; Maiorino K; Nielson WR; Körner A; Peláez S
    Disabil Rehabil; 2019 Oct; 41(21):2506-2515. PubMed ID: 29741963
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of the nominal group technique to identify stakeholder priorities and inform survey development: an example with informal caregivers of people with scleroderma.
    Rice DB; Cañedo-Ayala M; Turner KA; Gumuchian ST; Malcarne VL; Hagedoorn M; Thombs BD;
    BMJ Open; 2018 Mar; 8(3):e019726. PubMed ID: 29500214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scleroderma patient perspectives on social support from close social relationships.
    Milette K; Thombs BD; Dewez S; Körner A; Peláez S
    Disabil Rehabil; 2020 Jun; 42(11):1588-1598. PubMed ID: 30761932
    [No Abstract]   [Full Text] [Related]  

  • 14. Development and preliminary validation of the Scleroderma Support Group Leader Self-efficacy Scale.
    Pal NE; Gumuchian ST; Delisle VC; Pépin M; Malcarne VL; Carrier ME; Kwakkenbos L; Peláez S; El-Baalbaki G; Thombs BD;
    J Scleroderma Relat Disord; 2018 Feb; 3(1):106-111. PubMed ID: 35382120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Support and information needs of people with systemic sclerosis by time since diagnosis: A cross-sectional study.
    Provencher S; Henry RS; Bacalao C; Carrier ME; Kwakkenbos L; Thombs BD;
    J Scleroderma Relat Disord; 2023 Oct; 8(3):247-252. PubMed ID: 37744044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a new patient-reported outcome measure to assess activities and participation in people with systemic sclerosis: the Cochin 17-item Scleroderma Functional scale.
    Daste C; Abdoul H; Foissac F; Papelard A; Alami S; Kwakkenbos L; Carrier ME; Lefèvre-Colau MM; Thombs BD; Poiraudeau S; Rannou F; Mouthon L; Nguyen C
    Br J Dermatol; 2020 Oct; 183(4):710-718. PubMed ID: 32017013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study.
    Azar M; Rice DB; Kwakkenbos L; Carrier ME; Shrier I; Bartlett SJ; Hudson M; Mouthon L; Poiraudeau S; van den Ende CHM; Johnson SR; Rodriguez Reyna TS; Schouffoer AA; Welling J; Thombs BD;
    Disabil Rehabil; 2018 Aug; 40(17):1997-2003. PubMed ID: 28478701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding coping strategies among people living with scleroderma: a focus group study.
    Gumuchian ST; Peláez S; Delisle VC; Carrier ME; Jewett LR; El-Baalbaki G; Fortune C; Hudson M; Körner A; Kwakkenbos L; Bartlett SJ; Thombs BD
    Disabil Rehabil; 2018 Dec; 40(25):3012-3021. PubMed ID: 28817964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.
    Showalter K; Merkel PA; Khanna D; Gordon JK
    J Scleroderma Relat Disord; 2020 Oct; 5(3):167-171. PubMed ID: 35382518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the beneficial experiences of online peer support for those affected by alopecia: an interpretative phenomenological analysis using online interviews.
    Iliffe LL; Thompson AR
    Br J Dermatol; 2019 Nov; 181(5):992-998. PubMed ID: 30972732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.